High materiality7/10
Evommune price target lowered to $22 from $28 at Leerink
Why it may matterVerify against the original reporting
Upside potential persists despite target downgrade.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
EVMN received an analyst target update from Leerink Partners.
- Leerink lowers EVMN target to $22; price now $10.89; upside remains.
Key facts
- 01
Target: $22
- 02
Posted price: $10.89
- 03
Analyst firm: Leerink Partners
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.